Vontobel Holding Ltd. Sells 248,546 Shares of Bristol Myers Squibb Company $BMY

Vontobel Holding Ltd. decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 24.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 763,128 shares of the biopharmaceutical company’s stock after selling 248,546 shares during the quarter. Vontobel Holding Ltd.’s holdings in Bristol Myers Squibb were worth $41,163,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. First National Bank of Omaha bought a new position in Bristol Myers Squibb during the 4th quarter worth approximately $233,000. Clarkston Capital Partners LLC lifted its stake in Bristol Myers Squibb by 1.8% in the fourth quarter. Clarkston Capital Partners LLC now owns 46,815 shares of the biopharmaceutical company’s stock valued at $2,525,000 after buying an additional 815 shares in the last quarter. Alchemi Wealth LLC bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $247,000. Martingale Asset Management L P lifted its stake in Bristol Myers Squibb by 13.4% in the fourth quarter. Martingale Asset Management L P now owns 546,873 shares of the biopharmaceutical company’s stock valued at $29,498,000 after buying an additional 64,681 shares in the last quarter. Finally, Korea Investment CORP lifted its stake in Bristol Myers Squibb by 8.4% in the fourth quarter. Korea Investment CORP now owns 1,494,455 shares of the biopharmaceutical company’s stock valued at $80,611,000 after buying an additional 115,975 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $57.05 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a market capitalization of $116.49 billion, a PE ratio of 16.02, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The firm’s 50 day moving average is $57.73 and its 200-day moving average is $56.87.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Barclays assumed coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target on the stock. Finally, HSBC lifted their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.